Carregant...
Cytotoxic and targeted therapy for hereditary cancers
There is a number of drugs demonstrating specific activity towards hereditary cancers. For example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the remaining BRCA allele, which makes them particularly sensitive to platinum-based drugs, PARP inhibitors (PARPi), mitom...
Guardat en:
| Publicat a: | Hered Cancer Clin Pract |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4994296/ https://ncbi.nlm.nih.gov/pubmed/27555886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13053-016-0057-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|